Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Lessened by Bronte Capital Management Pty Ltd.

Bronte Capital Management Pty Ltd. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 1.7% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 137,042 shares of the biopharmaceutical company’s stock after selling 2,412 shares during the period. Regeneron Pharmaceuticals accounts for approximately 12.5% of Bronte Capital Management Pty Ltd.’s portfolio, making the stock its 3rd largest position. Bronte Capital Management Pty Ltd. owned about 0.12% of Regeneron Pharmaceuticals worth $144,064,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. First National Trust Co raised its position in Regeneron Pharmaceuticals by 48.5% during the 3rd quarter. First National Trust Co now owns 306 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 100 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth about $665,000. Entropy Technologies LP purchased a new position in Regeneron Pharmaceuticals during the third quarter worth about $420,000. Nations Financial Group Inc. IA ADV lifted its position in Regeneron Pharmaceuticals by 3.5% in the third quarter. Nations Financial Group Inc. IA ADV now owns 1,082 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 37 shares during the period. Finally, Catalytic Wealth RIA LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $1,334,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Finally, Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,107.25.

Get Our Latest Analysis on REGN

Regeneron Pharmaceuticals Trading Down 0.3 %

Shares of REGN opened at $825.68 on Tuesday. The firm has a market capitalization of $90.73 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 3.13 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock’s fifty day simple moving average is $1,021.70 and its 200 day simple moving average is $1,038.20. Regeneron Pharmaceuticals, Inc. has a twelve month low of $784.96 and a twelve month high of $1,211.20.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.